Following on from the preclinical data generated using PTT-3213 and PTT-3196 in RCC-derived tumour models, Pathios has taken an optimised, lead candidate of its GPR65 inhibitor into the clinic. This evidence concerns the gene GPR65 and renal cell carcinoma.